IMPAX Laboratories, Inc. (IPXL) Announces Departure Of Carole Ben-Maimon, M.D., President Of Global Pharmaceuticals

IMPAX Laboratories, Inc. (IPXL) Announces Departure Of Carole Ben-Maimon, M.D., President Of Global Pharmaceuticals

HAYWARD, Calif., Oct. 22, 2014 /PRNewswire/ -- Impax Laboratories, Inc. (NASDAQ: IPXL)today announced that Carole Ben-Maimon, M.D., president of Global Pharmaceuticals, the Company's generic pharmaceutical division, has resigned for personal and family reasons. Dr. Ben-Maimon's resignation will be effective November 3, 2014.

Logo -

"For more than three years, Carole successfully managed the generic business by capitalizing on new product launches, advancing our market position, and expanding and diversifying our portfolio through business development and M&A opportunities," said Fred Wilkinson, president and CEO of Impax. "We will continue to benefit from improved business processes established under Carole. She has served as a great business partner during my short-time at Impax and her counsel will be missed"

"I am grateful for the relationships and support I have enjoyed over the past three years at Impax," said Dr. Ben-Maimon. "Impax is a great company, and I am confident that with its committed employees and under Fred's leadership, the company will continue to grow and successfully execute its growth strategy."

About Impax Laboratories, Inc.

Impax Laboratories, Inc. (Impax) is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams and ointments. For more information, please visit the Company's Web site at:

Company Contact:
Mark Donohue
Investor Relations and Corporate Communications
(215) 558-4526

SOURCE Impax Laboratories, Inc.

Suggested Articles

Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.

Merck's HIF-2α inhibitor, picked up in its $1 billion Peloton buyout, shrank kidney tumors in 36% of patients and showed promise in other tumors, too.

Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.